SpyGlass Pharma, Inc. Common Stock
SGP
Get informed when a big investor buys or sells
+ FollowMarket Cap$616.51M
Close$
$2.84
84.6% downside
Current Fair Value
84.6% downsideOvervalued by 84.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $616.51 Million |
|---|---|
| Enterprise Value | $379.22 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.19 |
| Beta | -0.34 |
| Outstanding Shares | 19,927,848 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -13.93 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 127.23%▲ 127.23% |
|---|---|
| Total Invested | $655.44M |
| Investors Holding | 35▲ 35.00% |
ESG Score
No data
About SpyGlass Pharma, Inc. Common Stock
1,489 employees
CEO: Patrick H. Mooney SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System)...